During the two-year project, BioRealm will collaborate with top addiction researchers to develop a roadmap for future clinical products. "An important part of this project will be building a framework for biomarker development, which may classify smokers and suggest smoking cessation therapies based on individual characteristics, including genetics," said Dr. James Baurley, Co-founder of BioRealm. "Our team will be developing state-of-the-art statistical methods that combine all available data to build predictive models. This includes biological information, existing study data, and Smokescreen data as it becomes available."
BioRealm is currently enrolling early-access users of the Smokescreen platform. Manufacturing of Smokescreen genotyping arrays is expected to begin in the fourth quarter of 2013. Additional information related to the Smokescreen product and early access could be found at https://biorealmresearch.com/smokescreen.
Founded in 2006, BioRealm develops solutions for genetic research and the biomedical industry.
This project has been funded in whole or in part with Federal funds from the National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN271201300004C.
Read the full story at http://www.prweb.com/releases/2013/8/prweb10985208.htm.
Copyright©2012 Vocus, Inc.
All rights reserved